Fed. Circ. Created Disclosure 'Anarchy,' Amgen Tells Justices
The Federal Circuit deviated from the Patent Act when it imposed different standards on the written description and enablement disclosures of a patent, Amgen Inc. told the U.S. Supreme Court in...To view the full article, register now.
Already a subscriber? Click here to view full article